- Home
- IKT vs HEQ Comparison
IKT vs HEQ Comparison
Compare IKT & HEQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKT
- HEQ
- Stock Information
- Founded
- IKT 2008
- HEQ 2011
- Country
- IKT United States
- HEQ United States
- Employees
- IKT N/A
- HEQ N/A
- Industry
- IKT Biotechnology: Pharmaceutical Preparations
- HEQ Investment Managers
- Sector
- IKT Health Care
- HEQ Finance
- Exchange
- IKT Nasdaq
- HEQ Nasdaq
- Market Cap
- IKT 140.5M
- HEQ 128.9M
- IPO Year
- IKT 2020
- HEQ N/A
- Fundamental
- Price
- IKT $1.85
- HEQ $10.54
- Analyst Decision
- IKT Buy
- HEQ
- Analyst Count
- IKT 2
- HEQ 0
- Target Price
- IKT $8.00
- HEQ N/A
- AVG Volume (30 Days)
- IKT 526.2K
- HEQ 43.1K
- Earning Date
- IKT 08-13-2025
- HEQ 01-01-0001
- Dividend Yield
- IKT N/A
- HEQ 9.78%
- EPS Growth
- IKT N/A
- HEQ N/A
- EPS
- IKT N/A
- HEQ N/A
- Revenue
- IKT N/A
- HEQ N/A
- Revenue This Year
- IKT N/A
- HEQ N/A
- Revenue Next Year
- IKT N/A
- HEQ N/A
- P/E Ratio
- IKT N/A
- HEQ N/A
- Revenue Growth
- IKT N/A
- HEQ N/A
- 52 Week Low
- IKT $1.12
- HEQ $9.08
- 52 Week High
- IKT $4.20
- HEQ $11.84
- Technical
- Relative Strength Index (RSI)
- IKT 47.71
- HEQ 48.61
- Support Level
- IKT $1.80
- HEQ $10.45
- Resistance Level
- IKT $2.09
- HEQ $10.73
- Average True Range (ATR)
- IKT 0.14
- HEQ 0.08
- MACD
- IKT 0.03
- HEQ -0.01
- Stochastic Oscillator
- IKT 54.72
- HEQ 47.22
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
About HEQ John Hancock Hedged Equity & Income Fund of Beneficial Interest
John Hancock Hedged Equity & Income Fund is a closed-end management investment company. Its investment objective is to provide total return with a focus on current income and gains and also consisting of long-term capital appreciation. It invests in various sectors such as financials, consumer discretionary, information technology, energy, healthcare, materials, real estate, consumer staples, short-term investments, and others.